D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents’ strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio